Buprenorphine Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-05　·　168 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 2,780.6 Mn
2033 年預估規模: USD 4,316.9 Mn
年複合成長率 CAGR: 9.1%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-05頁數 168報告編號 CMI4237

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Buprenorphine Market, By Brand (Sublocade (buprenorphine extendedrelease), Suboxone (buprenorphine and naloxone), Brixadi (buprenorphine extendedrelease), Zubsolv (buprenorphine and naloxone), and Others (Belbuca, Butrans and among others)), By Type (Branded and Generics), By Route of Administration (Injectable (Intravenous, Intramuscular, Subcutaneous), Sublingual, Buccal, Transdermal, and Others), By Dosage Form (Injectable Solutions, Patches, Films, Others (Tablets, etc.)), By Indication (Opioid Use Disorder (OUD), Pain Management, Acute Pain, Chronic Pain), By Formulation Type (Single Drug Formulation, Fixed Dose Combination), By Age Group (Adults, Pediatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

報告摘要

Buprenorphine is the first medication to treat opioid use disorder that may be prescribed or distributed in doctor's offices, vastly expanding access to care. Buprenorphine should be prescribed as a component of a thorough treatment plan that includes counseling and other services to give patients a whole-person approach, as is the case with all drugs used in therapy. Buprenorphine provides a number of benefits for those with opioid use disorder and for those for whom therapy at an opioid treatment center is uncomfortable or inappropriate. The following buprenorphine products are approved for the treatment of opioid use disorder by the U.S. FDA: • Generic buprenorphine/naloxone sublingual tablets • Buprenorphine sublingual tablets (Subutex) • Buprenorphine/naloxone sublingual films (Suboxone) • Buprenorphine/naloxone sublingual tablets (Zubsolv) • Buprenorphine/naloxone buccal film (Bunavail) • Buprenorphine implants (Probuphine) • Buprenorphine extended-release injection (Sublocade) Market Dynamics Increasing approval of buprenorphine by regulatory authorities for subcutaneous use is expected to increase the global buprenorphine market over the forecast period. For instance, in March, 2018, Indivior PLC, a pharmaceutical company, announced that SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use (CIII), is available in the U.S. The U.S. Food and Drug Administration (FDA) has granted approval for the use of SUBLOCADE for the treatment of moderate to severe opioid use disorder (OUD) in adult patients who have started therapy with a transmucosal buprenorphine-containing medication and have undergone dose titration for at least seven days. It should only be given by medical professionals, and it should be part of a comprehensive treatment plan that also includes counseling and psychosocial support. Key features of the study • This report provides in-depth analysis of the global buprenorphine market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global buprenorphine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study are Mallinckrodt, Noramco, Unichem Laboratories Ltd., Sanofi, Johnson Matthey, Arevipharma Gmbh, Resonance Laboratories Pvt. Ltd., Sun Pharmaceutical Industries Limited, Rusan Pharma Ltd. Micro Orgo Chem, Faran Shimi Pharmaceutical, Indivior PLC, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC. • Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global buprenorphine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global buprenorphine market Market Segmentation • Brand Insights (Revenue, USD Mn, 2021 - 2033) o Sublocade (buprenorphine extendedrelease) o Suboxone (buprenorphine and naloxone) o Brixadi (buprenorphine extendedrelease) o Zubsolv (buprenorphine and naloxone) o Others (Belbuca, Butrans and among others) • Type Insights (Revenue, USD Mn, 2021 - 2033) o Branded o Generics • Route of Administration Insights (Revenue, USD Mn, 2021 - 2033) o Injectable  Intravenous  Intramuscular  Subcutaneous o Sublingual o Buccal o Transdermal o Others • Dosage Form Insights (Revenue, USD Mn, 2021 - 2033) o Injectable Solutions o Patches o Films o Others (Tablets, etc.) • Indication Insights (Revenue, USD Mn, 2021 - 2033) o Opioid Use Disorder (OUD) o Pain Management o Acute Pain o Chronic Pain • Formulation Type Insights (Revenue, USD Mn, 2021 - 2033) o Single Drug Formulation o Fixed Dose Combination • Age Group Insights (Revenue, USD Mn, 2021 - 2033) o Adults o Pediatric • Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • Regional Insights (Revenue, USD Mn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Indivior o Braeburn o Camurus o Collegium Pharmaceutical o Teva Pharmaceuticals o Hikma Pharmaceuticals USA o Alvogen o Camber Pharmaceuticals o Apotex o Dr Reddy’s Laboratories o Orexo o Rusan Pharma o Arevipharma o Noramco o Neuraxpharm

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Buprenorphine Market, By Brand  Global Buprenorphine Market, By Type  Global Buprenorphine Market, By Route of Administration  Global Buprenorphine Market, By Dosage Form  Global Buprenorphine Market, By Indication  Global Buprenorphine Market, By Formulation Type  Global Buprenorphine Market, By Age Group  Global Buprenorphine Market, By Distribution Channel  Global Buprenorphine Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Key Developments o Industry Trends 4. Global Buprenorphine Market, By Brand, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Sublocade (buprenorphine extendedrelease)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Suboxone (buprenorphine and naloxone)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Brixadi (buprenorphine extendedrelease)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Zubsolv (buprenorphine and naloxone)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others (Belbuca, Butrans and among Others)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 5. Global Buprenorphine Market, By Type, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Branded  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Generics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 6. Global Buprenorphine Market, By Route of Administration, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Injectable  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Intravenous o Intramuscular o Subcutaneous o Sublingual  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Buccal  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Transdermal  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 7. Global Buprenorphine Market, By Dosage Form, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Injectable Solutions  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Patches  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Films  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others (Tablets, etc.)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 8. Global Buprenorphine Market, By Indication, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Opioid Use Disorder (OUD)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Pain Management  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Acute Pain  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Chronic Pain  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 9. Global Buprenorphine Market, By Formulation Type, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Single Drug Formulation  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Fixed Dose Combination  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 10. Global Buprenorphine Market, By Age Group, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Adults  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Pediatric  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 11. Global Buprenorphine Market, By Distribution Channel, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Online Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 12. Global Buprenorphine Market, By Region, 2021 - 2033, Value (USD Mn) o Introduction  Market Share (%) Analysis, 2026,2029 & 2033, Value (USD Mn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Formulation Type, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn) o South Africa o North Africa o Central Africa 13. Competitive Landscape o Indivior  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Braeburn  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Camurus  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Collegium Pharmaceutical  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Teva Pharmaceuticals  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Hikma Pharmaceuticals USA  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Alvogen  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Camber Pharmaceuticals  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Apotex  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Dr Reddy’s Laboratories  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Orexo  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Rusan Pharma  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Arevipharma  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Noramco  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Neuraxpharm  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 14. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 15. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on 'Buprenorphine Market' - Global forecast to 2033

提及公司

IndiviorBraeburnCamurusCollegium PharmaceuticalTeva PharmaceuticalsHikma Pharmaceuticals USAAlvogenCamber PharmaceuticalsApotexDr Reddy’s LaboratoriesOrexoRusan PharmaArevipharmaNoramcoNeuraxpharm

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們